Comparative Pharmacology
Head-to-head clinical analysis: FIORICET W CODEINE versus WESTADONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FIORICET W CODEINE versus WESTADONE.
FIORICET W/ CODEINE vs WESTADONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FIORICET W/ CODEINE combines butalbital (barbiturate) that enhances GABA-A receptor activity, acetaminophen (analgesic/antipyretic) that inhibits cyclooxygenase and modulates cannabinoid receptors, and codeine (opioid mu-receptor agonist) that activates mu-opioid receptors to produce analgesia and antitussive effects.
Mu-opioid receptor agonist; also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake.
1-2 capsules orally every 4 hours as needed, maximum 6 capsules per day.
Oral: 2.5-10 mg every 4-6 hours as needed for pain; maximum 40 mg per day.
None Documented
None Documented
Codeine: 2.5-3.5 hours (converted to morphine; clinical effect wanes accordingly). Acetaminophen: 1.5-2.5 hours. Butalbital: 35-40 hours (prolonged in hepatic impairment; contributes to sedation). Caffeine: 3-5 hours.
Terminal elimination half-life: 15-60 hours (mean ~24 hours). Clinical context: Prolonged half-life supports once-daily dosing in opioid maintenance; accumulation occurs with repeated dosing due to long half-life.
Codeine and its metabolites are primarily excreted renally (about 90% as conjugates and free drug). Acetaminophen is excreted renally as conjugates (85-90%) and as unchanged drug (<5%). Butalbital is excreted renally (about 90% as metabolites and unchanged). Caffeine metabolites are excreted renally. Fecal excretion is minimal.
Primarily renal (40-50% as unchanged methadone and its metabolites, 15-20% as metadone-N-oxide), biliary/fecal (5-10%).
Category D/X
Category C
Opioid Agonist
Opioid Agonist